8OEG
| PDE4B bound to MAPI compound 92a | Descriptor: | MAGNESIUM ION, ZINC ION, [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl-pyridin-4-yl]-1-(3,4-dimethoxyphenyl)ethyl] 5-[[[(1~{R})-2-[[(3~{R})-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxidanylidene-1-phenyl-ethyl]amino]methyl]thiophene-2-carboxylate, ... | Authors: | Rizzi, A, Armani, E. | Deposit date: | 2023-03-10 | Release date: | 2023-04-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.89 Å) | Cite: | Optimization of M 3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. J.Med.Chem., 66, 2023
|
|
5OHJ
| Human phosphodiesterase 4B catalytic domain in complex with a pyrrolidinyl inhibitor. | Descriptor: | MAGNESIUM ION, ZINC ION, [(1~{S})-2-[3,5-bis(chloranyl)-1-oxidanyl-pyridin-1-ium-4-yl]-1-[4-[bis(fluoranyl)methoxy]-3-(cyclopropylmethoxy)phenyl]ethyl] (2~{S})-1-[3-(dimethylcarbamoyl)phenyl]sulfonylpyrrolidine-2-carboxylate, ... | Authors: | Rizzi, A, Carzaniga, L, Armani, E. | Deposit date: | 2017-07-17 | Release date: | 2017-12-13 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases. J. Med. Chem., 60, 2017
|
|
3JTG
| Crystal structure of mouse Elf3 C-terminal DNA-binding domain in complex with type II TGF-beta receptor promoter DNA | Descriptor: | DNA (5'-D(*CP*AP*AP*AP*CP*AP*GP*GP*AP*AP*AP*CP*TP*CP*CP*T)-3'), DNA (5'-D(*GP*AP*GP*GP*AP*GP*TP*TP*TP*CP*CP*TP*GP*TP*TP*T)-3'), ETS-related transcription factor Elf-3 | Authors: | Tahirov, T.H, Babayeva, N.D, Agarkar, V.B, Rizzino, A. | Deposit date: | 2009-09-11 | Release date: | 2010-01-12 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Crystal structure of mouse Elf3 C-terminal DNA-binding domain in complex with type II TGF-beta receptor promoter DNA. J.Mol.Biol., 397, 2010
|
|
6DBP
| |
4OUA
| Coexistent single-crystal structure of latent and active mushroom tyrosinase (abPPO4) mediated by a hexatungstotellurate(VI) | Descriptor: | 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, 6-tungstotellurate(VI), COPPER (I) ION, ... | Authors: | St.Mauracher, G, Molitor, C, Al-Oweini, R, Kortz, U, Rompel, A. | Deposit date: | 2014-02-15 | Release date: | 2014-06-25 | Last modified: | 2018-01-31 | Method: | X-RAY DIFFRACTION (2.763 Å) | Cite: | Latent and active abPPO4 mushroom tyrosinase cocrystallized with hexatungstotellurate(VI) in a single crystal. Acta Crystallogr.,Sect.D, 70, 2014
|
|
3MFK
| |
6HJT
| The X-ray structure of the horse spleen ferritin nanocage containing Pt, obtained upon encapsulation of a Pt(II) terpyridine compound within the protein cage | Descriptor: | CADMIUM ION, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | Authors: | Pica, A, Ferraro, G, Merlino, A. | Deposit date: | 2018-09-04 | Release date: | 2018-12-19 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.33 Å) | Cite: | Preparation, structure, cytotoxicity and mechanism of action of ferritin-Pt(II) terpyridine compound nanocomposites. Nanomedicine (Lond), 13, 2018
|
|
6HJU
| The X-ray structure of the horse spleen ferritin nanocage containing Pt, obtained upon encapsulation of a Pt(II) terpyridine compound within the protein cage | Descriptor: | CADMIUM ION, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | Authors: | Pica, A, Ferraro, G, Merlino, A. | Deposit date: | 2018-09-04 | Release date: | 2018-12-19 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.58 Å) | Cite: | Preparation, structure, cytotoxicity and mechanism of action of ferritin-Pt(II) terpyridine compound nanocomposites. Nanomedicine (Lond), 13, 2018
|
|
6G5Y
| |
6G5V
| |
4L0Y
| |
4L18
| |
4L0Z
| |